NCT01589861终止1 期
A Phase Ib/II Open-label Study Evaluating Safety and Efficacy of Oral BKM120 in Combination With Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Locally Advanced, Recurrent and Metastatic Breast Cancer. PIKHER2/IPC 2011-001
Institut Paoli-Calmettes2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2011年12月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- Phase Ib: maximum-tolerated dose (MTD)
研究概览
简要总结
This study is based upon the following points:
- Resistance to trastuzumab, either primary or secondary, is a clinically relevant issue.
- PI3K/AKT activation, due to loss of expression/function of PTEN and/or activating mutations of PIK3CA, is a mechanism of resistance with clinical relevance in breast cancer. Such activation can be detected by:
- IHC evaluation of PTEN protein expression
- genotyping of PIK3CA exon 9 and 20
- IHC evaluation of phospho-AKT expression
- BKM120 is an effective PI3K inhibitor. BKM120 and anti-HER2 therapy may have a synergistic antitumor activity in preclinical model of HER2+ breast cancer.
- Lapatinib is an effective anti-HER2 therapy in trastuzumab-resistant disease.
- For the evaluation of novel targeted therapies, selecting a patient population enriched for activation of the target to be modulated should allow to maximize the differences in clinical outcome that are expected in the experimental arm, and thus to minimize the patient number to include.
- We propose to test in a phase I/II study the combination of lapatinib and BKM120 in trastuzumab-resistant HER2+ MBC patients, enriched for activation of PI3K/AKT as detected by loss of expression of PTEN (IHC), and/or mutation of PIK3CA and/or overexpression of phospho-AKT (IHC). Only for phase II patients, mutational status will be an inclusion criteria. For phase I patients molecular status will be a retrospective exploratory analysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female or male ≥ 18 years
- •WHO performance status ≤ 1
- •Locally advanced, recurrent or metastatic, histologically confirmed HER2 positive (IHC 3+ or FISH positive) breast cancer after failure of trastuzumab treatment.
- •while on trastuzumab or within 4 weeks since the last infusion of trastuzumab for metastatic disease within 12 months of the last infusion for patients who received trastuzumab as adjuvant or neoadjuvant treatment
- •For the phase II part, progression on trastuzumab must have occurred within 16 weeks before entering this trial.
- •should not have received more than 3 lines of anti-HER2 therapy.
- •For the phase II part, activation of PI3K/AKT pathway
- •capable of understanding the protocol and has signed the informed consent
- •laboratory values within normal range
- •Measurable disease
- •Patients may have received treatment for brain metastases, but must be neurologically stable
- •Baseline LVEF>50% (MUGA or ECHO)
- •Affiliation to social security
排除标准
- •Previous treatment with lapatinib, neratinib or a PI3K inhibitor
- •untreated brain metastases.
- •acute or chronic liver, renal disease or pancreatitis
- •any peripheral neuropathy ≥ CTCAE grade 2
- •any of the following mood disorders, or meets the cut-off score of ≥ 10 in the PHQ-9 or a cut-off of ≥ 15 in the GAD-7 mood scale, respectively, or selects a positive response of '1, 2, or 3' to question number 9 regarding potential for suicidal thoughts ideation in the PHQ-9 (independent of the total score of the PHQ-9)
- •Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)
- •≥ CTCAE grade 3 anxiety
- •diarrhea ≥ CTCAE grade 2
- •active cardiac disease
- •history of cardiac dysfunction
- •poorly controlled diabetes mellitus (HbA1c > 8 %)
- •Other severe and/or uncontrolled concomitant medical conditions
- •Impairment of gastrointestinal function that may significantly alter the absorption of BKM120
- •been treated with any hematopoietic colony-stimulating growth factors ≤ 2 weeks prior to starting study drug.
- •currently receiving treatment with medication with a known risk prolong the QT interval or inducing Torsades de Pointes
- •currently being treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A
- •receiving chronic treatment with steroids or another immunosuppressive agent.
- •have received chemotherapy or targeted anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies [other than trastuzumab] or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy
- •have received small molecule therapeutics (excluding monoclonal antibodies) ≤ 5 effective half lives prior to starting study drug or who have not recovered from side effects of such therapy
- •have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
- •have undergone major surgery ≤ 28 days prior to starting study drug or who have not recovered from side effects of such therapy
- •Known diagnosis of HIV infection
- •History of another malignancy within 3 years
- •Patient is unable or unwilling to abide by the study protocol
- •pregnant or breast feeding women
研究组 & 干预措施
BKM120+Lapatinib
Experimental
BKM120 40, 60 or 80 mg/day per os for 28 days cycle
+ Lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle
干预措施: BKM120 + lapatinib (Drug)
结局指标
主要结局
Phase Ib: maximum-tolerated dose (MTD)
时间窗: Day 28
To determine the maximum-tolerated dose (MTD) of BKM120 when administered orally in combination with daily lapatinib to adult patients trastuzumab-resistant HER2+ locally advanced, recurrent and metastatic breast cancer.
Phase II: objective response rate (ORR)
时间窗: until progression assessed up to 1 year
To determine the efficacy of daily BKM120 in combination with daily lapatinib as measured by objective response rate (ORR), defined by complete response (CR) or partial response (PR) of target and non target lesions according to RECIST V1.1., in patients with activation of PI3K/AKT pathway detected according to one at least of the following criteria, measured on primary or metastatic tissue: PTEN negative by IHC and/or somatic mutations (exons 9 and 20) of PIK3CA and/or Overexpression of phospho-AKT by IHC.
次要结局
- safety(until progression or end of treatment assessed up to 1 year)
- progression-free survival (PFS)(until progression assessed up to 1 year)
- clinical benefit (CB)(until progression assessed up to 1 year)
- pharmacokinetics(D1, D8, D15, D22, D28 post dose)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous MeningitisCarcinomatous MeningitisMetastatic Breast CancerNCT01373710Institut Curie34
已完成
1 期
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic FunctionBreast CancerNCT01513083Hoffmann-La Roche28
进行中（未招募）
2 期
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)Breast CancerNCT04383275Fudan University367
尚未招募
2 期
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)Breast CancerNCT04922008Fudan University356
已完成
2 期
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOXMetastatic or Recurrent Gastric AdenocarcinomaHer-2 Positive Gastric CancerNCT01396707Asan Medical Center55